Vanguard Group Inc. Buys 1,360,613 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Vanguard Group Inc. lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 5.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,492,486 shares of the biopharmaceutical company’s stock after acquiring an additional 1,360,613 shares during the quarter. Vanguard Group Inc. owned approximately 9.65% of Amicus Therapeutics worth $404,308,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in Amicus Therapeutics by 101.9% in the fourth quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after buying an additional 7,666,335 shares during the period. American International Group Inc. lifted its stake in shares of Amicus Therapeutics by 0.9% in the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock valued at $2,004,000 after purchasing an additional 1,298 shares during the period. Teachers Retirement System of The State of Kentucky bought a new stake in shares of Amicus Therapeutics during the 4th quarter valued at about $1,178,000. Perceptive Advisors LLC grew its stake in Amicus Therapeutics by 1.3% during the fourth quarter. Perceptive Advisors LLC now owns 28,057,456 shares of the biopharmaceutical company’s stock worth $398,135,000 after purchasing an additional 364,539 shares during the period. Finally, Old Well Partners LLC acquired a new position in Amicus Therapeutics in the fourth quarter valued at approximately $180,000.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $10.07, for a total value of $75,525.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,928,605.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.20% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a research note on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a report on Thursday, February 29th. JPMorgan Chase & Co. reduced their target price on Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Monday, March 18th. Morgan Stanley dropped their price target on Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. Finally, UBS Group reduced their price objective on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, May 10th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.57.

Amicus Therapeutics Stock Up 2.2 %

Shares of NASDAQ:FOLD opened at $9.91 on Friday. The stock has a market cap of $2.94 billion, a price-to-earnings ratio of -20.22 and a beta of 0.74. The company has a quick ratio of 2.61, a current ratio of 3.03 and a debt-to-equity ratio of 2.97. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The business’s 50 day moving average is $10.00 and its 200 day moving average is $11.71.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.04. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The business had revenue of $110.40 million for the quarter, compared to analysts’ expectations of $111.19 million. During the same period last year, the business earned ($0.18) EPS. The business’s revenue was up 27.9% on a year-over-year basis. On average, sell-side analysts forecast that Amicus Therapeutics, Inc. will post -0.12 earnings per share for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.